<?xml version="1.0" encoding="UTF-8"?>
<p>A second infection, with other DENV serotypes, can be more severe and lethal than the first one. Commonly, DHF and DSS occur in this context, presenting more severe forms of symptoms, such as fever, thrombocytopenia, hemorrhagic manifestations, and hypovolemia (
 <xref rid="cytoa24047-bib-0007" ref-type="ref">7</xref>). Studies have demonstrated that the presence of cross‐reactive antibodies against different DENV serotypes predisposes the enhanced illness (
 <xref rid="cytoa24047-bib-0008" ref-type="ref">8</xref>) and contributes to the development of DHF and DSS (
 <xref rid="cytoa24047-bib-0009" ref-type="ref">9</xref>). These non‐neutralizing preexisting antibodies can be obtained from previous infection, maternal passive immunity, or vaccination.
</p>
